CTLA4 and neoplasm: We examined the publicly accessible scRNA-seq data of 48 tumor biopsy samples obtained either pre- or post-treatment from patients (n = 32) with metastatic melanoma treated with anti-PD1 (n = 24) or anti-PD1+anti-CTLA4 (n = 8), as published (9).